MediWound Ltd. (MDWD) stock
MDWDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$13.55+0.65 (+5.04%)
Close on Nov 16, 2026Market cap $173.92MP/E –Yield –
MediWound r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $14.32M, up 61.3% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $14.32M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.32M | +61.3% |
| FY2024 | Dec 31, 2024 | $8.88M | +18.9% |
| FY2023 | Dec 31, 2023 | $7.47M | -26.7% |
| FY2022 | Dec 31, 2022 | $10.18M | -0.7% |
| FY2021 | Dec 31, 2021 | $10.26M | +33.2% |
| FY2020 | Dec 31, 2020 | $7.70M | +54.9% |
| FY2019 | Dec 31, 2019 | $4.97M | +22.0% |
| FY2018 | Dec 31, 2018 | $4.07M | -25.4% |
| FY2017 | Dec 31, 2017 | $5.46M | -22.7% |
| FY2016 | Dec 31, 2016 | $7.07M | +17.4% |
| FY2015 | Dec 31, 2015 | $6.02M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.90M | +169.3% |
| Q2 FY2025 | Jun 30, 2025 | $3.49M | +31.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.90M | +17.7% |
| Q2 FY2023 | Jun 30, 2023 | $2.02M | +1076.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.19M | +42.6% |
| Q2 FY2021 | Jun 30, 2021 | $2.66M | +59.6% |
| Q2 FY2020 | Jun 30, 2020 | $1.61M | – |
| Q2 FY2019 | Jun 30, 2019 | $172.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $1.54M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.66M | – |
See a number that looks wrong?